Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Releases Earnings Results, Misses Expectations By $0.74 EPS

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) released its earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74), Yahoo Finance reports. Calliditas Therapeutics AB (publ) had a negative return on equity of 133.08% and a negative net margin of 40.19%. The company had revenue of $28.43 million during the quarter, compared to analyst estimates of $35.78 million.

Calliditas Therapeutics AB (publ) Trading Down 1.5 %

NASDAQ CALT opened at $22.42 on Friday. The company’s fifty day simple moving average is $20.60 and its 200-day simple moving average is $21.15. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $29.30. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The stock has a market cap of $667.89 million, a P/E ratio of -13.67 and a beta of 1.50.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on shares of Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.